Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Circular RNAs [[electronic resource] ] : Biogenesis and Functions / / edited by Junjie Xiao
| Circular RNAs [[electronic resource] ] : Biogenesis and Functions / / edited by Junjie Xiao |
| Edizione | [1st ed. 2018.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2018 |
| Descrizione fisica | 1 online resource (235 pages) |
| Disciplina | 573.21 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Human genetics
Biochemistry Cell biology Human Genetics Biochemistry, general Cell Biology |
| ISBN | 981-13-1426-8 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1 An overview of circular RNAs -- Chapter 2 RNA-sequencing and the predictions tools for circular RNAs -- Chapter 3 Online databases and circular RNAs -- Chapter 4 Circular RNA splicing -- Chapter 5 Circular RNAs biogenesis in eukaryotes through self-cleaving hammerhead ribozymes -- Chapter 6 Circular RNAs act as miRNA sponges -- Chapter 7 Regulation of transcription by Circular RNAs -- Chapter 8 Functional Analysis of Circular RNAs -- Chapter 9 Circular RNA in Exosomes -- Chapter 10 Circular RNAs in Blood -- Chapter 11 Circular RNA in Saliva -- Chapter 12 Emerging role of circular RNAs as potential biomarkers for the diagnosis of Human Diseases -- Chapter 13 Circular RNAs as novel biomarkers for cardiovascular diseases -- Chapter 14 Circular RNAs as biomarkers for cancer -- Chapter 15 Circular RNAs in cardiovascular diseases -- Chapter 16 Circular RNAs and Neuronal Development -- Chapter 17 Circular RNAs in Cancer -- Chapter 18 Circular RNAs in Brain Physiology and Disease -- Chapter 19 Circular RNA and Alzheimer’s Disease -- Chapter 20 Circular RNA in Liver: Health and Diseases -- Chapter 21 Circular RNAs in Organ Fibrosis -- Chapter 22 Circular RNAs in Metabolic Diseases -- Chapter 23 Circular RNAs in vascular functions and diseases -- Chapter 24 Functional role of circular RNA in regenerative medicine -- Chapter 25 The role of circular RNAs in cerebral ischemic diseases: ischemic stroke and cerebral ischemia/reperfusion injury -- Chapter 26 CircRNAs in plants -- Chapter 27 Circular RNAs and plant stress responses -- Chapter 28 Prospective advances in circular RNA investigation. |
| Record Nr. | UNINA-9910298439103321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Exercise for Cardiovascular Disease Prevention and Treatment [[electronic resource] ] : From Molecular to Clinical, Part 2 / / edited by Junjie Xiao
| Exercise for Cardiovascular Disease Prevention and Treatment [[electronic resource] ] : From Molecular to Clinical, Part 2 / / edited by Junjie Xiao |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2017 |
| Descrizione fisica | 1 online resource (VII, 387 p. 39 illus., 33 illus. in color.) |
| Disciplina | 616.1 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Human physiology
Molecular biology Cardiology Human Physiology Molecular Medicine |
| ISBN | 981-10-4304-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I: Overview -- Chapter 1: Physical inactivity and the economic and health burdens due to cardiovascular disease: exercise as medicine (Mark Hamer) -- Part II: Cardiac Exercise Physiology -- Chapter 2: Acute and chronic response to exercise in athletes: the “Supernormal Heart (Antonello D’Andrea) -- Chapter 3: The effects of exercise on cardiovascular biomarkers: new insights, recent data, and applications (Lin Che) -- Chapter 4: Acute and chronic exercise in animal models (Vu Thi Thu) -- Part III: Cardiac Cells Adaptations in Exercise -- Chapter 5 Structural, contractile and electrophysiological adaptations of cardiomyocytes to chronic exercise (Krzesiak A) -- Chapter 6: Formation of new cardiomyocytes in exercise (Liang Shen) -- Chapter 7: Physical exercise can spur beneficial neoangiogenesis and microvasculature remodeling within the heart - our salvation? (Michal Miko) -- Chapter 8 The non-cardiomyocyte cells of heart. their possible roles in exercise-based cardiac regeneration, reparation and remodeling (Ivan Varga) -- Part IV: Exercise benefits the Heart: Basic Science Evidence -- Chapter 9: Myocardial infarction and exercise training: evidence from basic science (Ivana Cinthya Moraes-Silva) -- Chapter 10: Cardiac ischemia/reperfusion injury (Juliana Pereira Borges) -- Chapter 11: Experimental evidences supporting the benefits of exercise training in heart failure (Marcelo H. A. Ichige) -- Chapter 12: Exercise amaliorates metabolic disturbances and oxidative stress in diabetic cardiomyopathy: possible underlying mechanisms (Ayman M. Mahmoud) -- Chapter 13: Cardiac aging – benefits of exercise, Nrf2 activation and antioxidant signaling (Madhusudhanan Narasimhan) -- Chapter 14: Cardiac fibrosis:the beneficial effects of exercise in cardiac fibrosis (Jan Kyselovič) -- Chapter 15: Physical exercise is a potential “medicine” for atherosclerosis (Jian Yang) -- Chapter 16: Experimental evidences supporting training-induced benefits in spontaneously hypertensive rats (Gustavo S. Masson) -- Chapter 17: Exercise training in pulmonary hypertension and right heart failure: insights from pre-clinical studies (Daniel Moreira-Gonçalves) -- Part V: Exercise benefits the Heart: Clinical Evidence -- Chapter 18: Coronary heart disease (Lei Wang) -- Chapter 19: Exercise exerts its beneficial effects on acute coronary syndrome：clinical evidence (Zhuyuan Liu) -- Chapter 20: Exercise-based rehabilitation for heart failure:clinical evidence (Rongjing Ding) -- Chapter 21: The benefits of exercise training on aerobic capacity in patients with Heart Failure and Preserved Ejection Fraction (Danilo Marcelo Leite do Prado) -- Chapter 22: Hypertension and exercise training: evidence from clinical studies (Ivana Cinthya Moraes-Silva) -- Chapter 23: Effects of exercise on arrhythmia (and viceversa): lesson from the Greek mythology (Caterina Lambiase) -- Chapter 24: Exercise and congenital heart disease (Junnan Wang) -- Chapter 25: The Positive Effects of Exercise in Chemotherapy-related Cardiomyopathy (Cavarretta Elena) -- Chapter 26: Clinical evidence of exercise benefits for stroke (Peipei Han) -- Chapter 27: Pulmonary hypertension (Abraham Samuel Babu) -- Chapter 28: Peripheral vascular disease (Basant Elnady) -- Part VI: Molecular Mechanisms -- Chapter 29 Molecular mechanisms (Kate L. Weeks) -- Chapter 30: NO Signaling in the cardiovascular system and exercise (Tiago Fernandes) -- Chapter 31: C/EBPB-CITED4 in exercised heart (Shengguang Ding) -- Chapter 32: MicroRNAs mediate beneficial effects of exercise in heart (Yihua Bei) -- Chapter 33: Exercise training and epigenetic regulation: multilevel modification and regulation of gene expression (Ursula Paula Renó Soci) -- Chapter 34: Exercise-induced mitochondrial adaptations in addressing heart failure (Jubert Marquez) -- Chapter 35: Exosomes mediate the beneficial effects of exercise (Yangxin Li) -- Part VII: Exercise Dosing and Prescription -- Chapter 36: Exercise dosing and prescription-Playing it safe: dangers and prescription (Lei Wang). |
| Record Nr. | UNINA-9910253953703321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Exercise for Cardiovascular Disease Prevention and Treatment [[electronic resource] ] : From Molecular to Clinical, Part 1 / / edited by Junjie Xiao
| Exercise for Cardiovascular Disease Prevention and Treatment [[electronic resource] ] : From Molecular to Clinical, Part 1 / / edited by Junjie Xiao |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2017 |
| Descrizione fisica | 1 online resource (VI, 324 p. 44 illus., 37 illus. in color.) |
| Disciplina | 616.105 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Human physiology
Molecular biology Cardiology Human Physiology Molecular Medicine |
| ISBN | 981-10-4307-8 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part I: Overview -- Chapter 1: Physical inactivity and the economic and health burdens due to cardiovascular disease: exercise as medicine (Mark Hamer) -- Part II: Cardiac Exercise Physiology -- Chapter 2: Acute and chronic response to exercise in athletes: the “Supernormal Heart (Antonello D’Andrea) -- Chapter 3: The effects of exercise on cardiovascular biomarkers: new insights, recent data, and applications (Lin Che) -- Chapter 4: Acute and chronic exercise in animal models (Vu Thi Thu) -- Part III: Cardiac Cells Adaptations in Exercise -- Chapter 5 Structural, contractile and electrophysiological adaptations of cardiomyocytes to chronic exercise (Krzesiak A) -- Chapter 6: Formation of new cardiomyocytes in exercise (Liang Shen) -- Chapter 7: Physical exercise can spur beneficial neoangiogenesis and microvasculature remodeling within the heart - our salvation? (Michal Miko) -- Chapter 8 The non-cardiomyocyte cells of heart. their possible roles in exercise-based cardiac regeneration, reparation and remodeling (Ivan Varga) -- Part IV: Exercise benefits the Heart: Basic Science Evidence -- Chapter 9: Myocardial infarction and exercise training: evidence from basic science (Ivana Cinthya Moraes-Silva) -- Chapter 10: Cardiac ischemia/reperfusion injury (Juliana Pereira Borges) -- Chapter 11: Experimental evidences supporting the benefits of exercise training in heart failure (Marcelo H. A. Ichige) -- Chapter 12: Exercise amaliorates metabolic disturbances and oxidative stress in diabetic cardiomyopathy: possible underlying mechanisms (Ayman M. Mahmoud) -- Chapter 13: Cardiac aging – benefits of exercise, Nrf2 activation and antioxidant signaling (Madhusudhanan Narasimhan) -- Chapter 14: Cardiac fibrosis:the beneficial effects of exercise in cardiac fibrosis (Jan Kyselovič) -- Chapter 15: Physical exercise is a potential “medicine” for atherosclerosis (Jian Yang) -- Chapter 16: Experimental evidences supporting training-induced benefits in spontaneously hypertensive rats (Gustavo S. Masson) -- Chapter 17: Exercise training in pulmonary hypertension and right heart failure: insights from pre-clinical studies (Daniel Moreira-Gonçalves) -- Part V: Exercise benefits the Heart: Clinical Evidence -- Chapter 18: Coronary heart disease (Lei Wang) -- Chapter 19: Exercise exerts its beneficial effects on acute coronary syndrome：clinical evidence (Zhuyuan Liu) -- Chapter 20: Exercise-based rehabilitation for heart failure:clinical evidence (Rongjing Ding) -- Chapter 21: The benefits of exercise training on aerobic capacity in patients with Heart Failure and Preserved Ejection Fraction (Danilo Marcelo Leite do Prado) -- Chapter 22: Hypertension and exercise training: evidence from clinical studies (Ivana Cinthya Moraes-Silva) -- Chapter 23: Effects of exercise on arrhythmia (and viceversa): lesson from the Greek mythology (Caterina Lambiase) -- Chapter 24: Exercise and congenital heart disease (Junnan Wang) -- Chapter 25: The Positive Effects of Exercise in Chemotherapy-related Cardiomyopathy (Cavarretta Elena) -- Chapter 26: Clinical evidence of exercise benefits for stroke (Peipei Han) -- Chapter 27: Pulmonary hypertension (Abraham Samuel Babu) -- Chapter 28: Peripheral vascular disease (Basant Elnady) -- Part VI: Molecular Mechanisms -- Chapter 29 Molecular mechanisms (Kate L. Weeks) -- Chapter 30: NO Signaling in the cardiovascular system and exercise (Tiago Fernandes) -- Chapter 31: C/EBPB-CITED4 in exercised heart (Shengguang Ding) -- Chapter 32: MicroRNAs mediate beneficial effects of exercise in heart (Yihua Bei) -- Chapter 33: Exercise training and epigenetic regulation: multilevel modification and regulation of gene expression (Ursula Paula Renó Soci) -- Chapter 34: Exercise-induced mitochondrial adaptations in addressing heart failure (Jubert Marquez) -- Chapter 35: Exosomes mediate the beneficial effects of exercise (Yangxin Li) -- Part VII: Exercise Dosing and Prescription -- Chapter 36: Exercise dosing and prescription-Playing it safe: dangers and prescription (Lei Wang). |
| Record Nr. | UNINA-9910253954103321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Exosomes in Cardiovascular Diseases [[electronic resource] ] : Biomarkers, Pathological and Therapeutic Effects / / edited by Junjie Xiao, Sanda Cretoiu
| Exosomes in Cardiovascular Diseases [[electronic resource] ] : Biomarkers, Pathological and Therapeutic Effects / / edited by Junjie Xiao, Sanda Cretoiu |
| Edizione | [1st ed. 2017.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2017 |
| Descrizione fisica | 1 online resource (VII, 307 p. 32 illus., 30 illus. in color.) |
| Disciplina | 616.107 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Molecular biology
Human physiology Cardiology Molecular Medicine Human Physiology |
| ISBN | 981-10-4397-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Section 1. Overview -- Section 2. Basic aspects of exosomes. -- Section 3. Exosomes as biomarkers of cardiovascular diseases. -- Section 4. Pathological Effects of Exosomes. -- Section 5. Therapeutic effects of Exosomes. -- Section 6. Future Prospects. |
| Record Nr. | UNINA-9910253937103321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2017 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Genome editing in cardiovascular and metabolic diseases / / Junjie Xiao, editor
| Genome editing in cardiovascular and metabolic diseases / / Junjie Xiao, editor |
| Pubbl/distr/stampa | Singapore : , : Springer, , [2023] |
| Descrizione fisica | 1 online resource (338 pages) |
| Disciplina | 616.1 |
| Collana | Advances in experimental medicine and biology |
| Soggetto topico | Cardiovascular system - Diseases |
| Soggetto non controllato |
Internal Medicine
Medical |
| ISBN |
9789811956423
9789811956416 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- Contributors -- Part I: Overview -- An Overview of Genome Editing in Cardiovascular and Metabolic Diseases -- 1 Genome-Editing Technologies -- 1.1 Nuclease Editing -- 1.2 Base Editing -- 1.3 Epigenome Editing -- 1.4 Other Types of Editing -- 2 Disease Modeling and Diagnostics -- 3 Therapeutic Genome Editing -- 4 Outlook -- References -- Part II: Bioinformatics -- Online Databases of Genome Editing in Cardiovascular and Metabolic Diseases -- 1 Cardiovascular and Metabolic Disease Genetic Basis -- 2 Significance of Genome Editing in Cardiovascular and Metabolic Diseases -- 3 Lung Genetic Disorders and Therapeutic Options -- 4 History and Genome Editing at Present -- 5 How to Perform a Genome Editing Experiment Nowadays (CRISPR-Cas) -- 5.1 Molecular Mechanism and Components of the CRISPR-Cas System -- 6 How to Prepare a CRISPR-Cas Experiment -- 7 Different Types of CRISPR-Cas-Based System -- 8 Off-Target Effect, Predictive Tools, and Strategies to Avoid Them -- 9 Guide RNA Designing and Available Online Tools and Databases -- 10 Transfection Mechanisms -- 11 Cardiovascular and Metabolic Disease Genome Editing in the Field -- 12 Experiments Using CRISPR-Cas9 -- 12.1 PRKAG2 Cardiac Syndrome -- 12.2 MYH7 Dysfunction -- 13 Experiments Using TALENs -- 13.1 PLN-Associated Hereditary Heart Failure -- 13.2 Obesity and LepR -- 14 Experiments Using ZFN -- 14.1 FBN1 and Marfan Syndrome -- References -- Part III: Genome Editing in Cardiovascular Disease -- Genome Editing and Cardiac Regeneration -- 1 Background -- 2 Scope of Cardiac Regeneration -- 2.1 Understanding Cardiac Regeneration from Animal Models -- 2.2 Developing Approaches for Cardiac Regeneration -- 3 Pathways and Regulators of Cardiac Regeneration -- 3.1 Hippo Signaling Pathway -- 3.2 Wnt Signaling Pathway -- 3.3 PI3K-AKT Signaling Pathway.
4 Approaches to Cardiac Regeneration -- 4.1 Genome Editing of Endogenous Cells to Initiate Cardiac Repair -- 4.1.1 In Situ Promotion of Proliferation and Cell Cycle Re-entry -- 4.1.2 In Vivo Trans-differentiation of Cardiac Fibroblasts -- 4.2 Transplantation of Exogenous Cells -- 5 Perspective -- References -- Genome Editing and Myocardial Development -- 1 Overview -- 2 Cardiac Development -- 2.1 Early Development and Cardiac Crescent -- 2.2 Cardiac Looping -- 2.3 Atrium, Sino Atrial Node, and Atrial Ventricular Node Development -- 2.4 Ventricular Development -- 2.5 Atrioventricular Valve Development -- 2.6 Outflow Track Development -- 2.7 Conductance System -- 3 Genetic Archetypes in Cardiac Development -- 4 Genetic Archetypes for Syndromic Congenital Heart Defects -- 5 Genetic Archetypes of Nonsyndromic Isolated Congenital Heart Defects -- 6 Genetic Archetypes for Left-Right Patterning -- 7 Genetic Archetypes of Inherited Arrhythmias -- 7.1 Long QT Syndromes -- 7.2 Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) -- 7.3 Brugada Syndromes (BrS) -- 7.4 Short QT Syndrome (SQTS) -- 8 Genetic Archetypes of Inherited Cardiomyopathy -- 8.1 Dilated Cardiomyopathy (DCM) -- 8.2 Hypertrophic Cardiomyopathy (HCM) -- 8.3 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) -- 8.4 Restrictive Cardiomyopathy (RCM) -- 8.5 Left Ventricular Non-compaction Cardiomyopathy -- 8.6 Cardiomyopathy in Other Disorders -- 9 Genome Editing in Modeling Inheritable Heart Diseases in Model Organisms -- 10 Other Considerations -- 11 Conclusions -- References -- Genome Editing and Heart Failure -- 1 Introduction -- 2 Pathophysiology of Heart Failure -- 3 Management of Heart Failure with a Reduced Ejection Fraction -- 4 Management of Heart Failure with a Preserved Ejection Fraction -- 5 The Genetic Architecture of Heart Failure -- 6 Tools for Genome Editing. 7 Genome Editing in Heart Failure -- 8 Using Genome Editing to Create In Vitro and In Vivo Disease Models of Heart Failure -- 9 Genome Editing for Therapy of Heart Failure -- 10 Conclusions -- References -- Genome Editing and Pathological Cardiac Hypertrophy -- 1 Introduction -- 2 Genetic Backgrounds of Cardiomyopathies -- 2.1 HCM and DCM -- 2.2 Arrhythmogenic Right Ventricular Cardiomyopathy -- 2.3 Restrictive Cardiomyopathy -- 2.4 Left Ventricular Noncompaction Cardiomyopathy (LVNC) -- 3 Genome Editing in Cell Models of Cardiac Disease -- 4 Genome Editing in Animal Models -- 5 Germline and Somatic Genome as a Therapeutic Implication and Ethical Problems -- 6 Hypertrophic Cardiomyopathy and Genome Editing -- 7 Duchenne Muscular Dystrophy and Genome Editing -- 8 Transthyretin Cardiac Amyloidosis -- 9 Long QT Syndrome -- 10 Future Directions in CRISPR and Cardiomyopathy Treatment -- 11 Advances in Nonviral Delivery System -- 12 Conclusions -- References -- Genome Editing and Diabetic Cardiomyopathy -- 1 Introduction -- 2 Diabetic Cardiomyopathy -- 3 Genetic Editing -- 4 Advancement in Genetic Editing Technology -- 5 Genetic Editing in Diabetic Cardiomyopathy -- 6 Future Direction -- References -- Genome Editing and Inherited Cardiac Arrhythmias -- 1 Introduction -- 2 Long QT Syndrome -- 3 Brugada Syndrome -- 3.1 Catecholaminergic Polymorphic Ventricular Tachycardia -- 4 Short QT Syndrome -- 5 Summary and Future Perspectives -- References -- Genome Editing and Atrial Fibrillation -- 1 Background -- 2 Genome Editing and Atrial Fibrillation -- 3 Atrial Fibrillation Substrate and Modifiable Electrical Targets -- 3.1 Ion Channels -- 3.2 Gap Junctions -- 3.3 Parasympathetic Signaling -- 4 Atrial Fibrillation Substrate and Modifiable Structural Aspects -- 4.1 Fibrosis -- 4.2 Apoptosis -- 5 Oxidative Stress and Modifiable Structural and Electrical Aspects. 5.1 ROS Generation and NADPH Oxidase -- 5.2 Oxidized Calmodulin-Dependent Protein Kinase II (oxCAMKII) -- 6 Conclusions -- References -- Genome Editing in Dyslipidemia and Atherosclerosis -- 1 Dyslipidemia and Atherosclerosis -- 2 Current Therapies of Dyslipidemia and Atherosclerosis -- 2.1 From Traditional Pharmacology to Targeted Therapy -- 2.2 Nucleic Acid-Based Therapy -- 3 Genome Editing -- 3.1 Evolution of Genome Editing Technology -- 3.2 In Vivo Delivery of Genome Editing Systems -- 4 Genome Editing in Dyslipidemia and Atherosclerosis -- 4.1 Genome Editing: A Driving Force for Dyslipidemia and Atherosclerosis Research -- 4.2 Preclinical Investigation of Genome Editing for Dyslipidemia and Atherosclerosis -- 4.3 Further Target Discovery for Dyslipidemia and Atherosclerosis -- 4.3.1 Gene and Variant Targets Inspired by Human Knockout -- 4.3.2 Candidate Genes and Variants from Large-Scale Genetic Studies -- 4.3.3 Driver Genes and Variants of Systems Genetic Studies -- 5 Concluding Remarks and Future Perspectives -- References -- Genome Editing to Abrogate Muscle Atrophy -- 1 Background -- 2 Muscle Atrophy -- 2.1 Aging -- 2.2 Nerve Injury -- 2.3 Immobilization -- 2.4 Fasting -- 2.5 Chronic Heart Failure -- 2.6 Cachexia -- 3 Protein Synthesis and Degradation in Muscle Atrophy -- 3.1 The Ubiquitin-Proteasome System -- 3.2 The Autophagy-Lysosome System -- 4 Molecular Pathways Underlying Muscle Atrophy -- 4.1 IGF1-Akt-FoxO Pathway -- 4.2 NF-kappaB Pathway -- 4.3 Myostatin Pathway -- 4.4 beta2-Adrenoceptor Pathway -- 5 Genome Editing in Muscle Atrophy -- 5.1 Genome Editing -- 5.1.1 Meganuclease -- 5.1.2 Zinc Finger Nuclease (ZFN) -- 5.1.3 Transcriptional Activation-Like Effector Nuclease (TALEN) -- 5.1.4 CRISPR/Cas9 System -- 5.2 Application of Genome Editing in Muscle Atrophy -- 6 Developing Approaches for Muscle Atrophy -- References. Part IV: Genome Editing in Metabolic Diseases -- Genome Editing and Obesity -- 1 Introduction -- 2 The Genetics Underlying Obesity -- 2.1 Monogenic Obesity -- 2.2 Polygenic Obesity -- 3 Currently Available Obesity Treatments -- 3.1 Dietary Changes, Exercise and Behaviour Therapy -- 3.2 Prescription Weight-Loss Medication -- 3.3 Metabolic Surgery -- 4 Latest Strategies for Obesity Treatment -- 4.1 Genome Editing Tools for Therapeutics in Obesity -- 5 Conclusions -- References -- Genome Editing and Fatty Liver -- 1 Background -- 1.1 Pathophysiology of Alcoholic Liver Disease -- 1.2 Pathophysiology of Nonalcoholic Fatty Liver Disease -- 2 Genetic Variants and Fatty Liver Disease -- 2.1 Candidate Gene Studies -- 2.2 GWAS Findings -- 2.3 Transmembrane 6 Superfamily 2 (TM6SF2) -- 2.4 Glucokinase Regulator (GCKR) -- 2.5 Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) -- 2.6 Membrane-Bound O-acetyltransferase Domain-Containing 7 (MBOAT7) -- 2.7 Heme Oxygenase (HMOX1) -- 2.8 Alcohol Dehydrogenase (ADH) and Aldehyde Dehydrogenase (ALDH) -- 3 Gene Editing Models for Fatty Liver Disease -- 3.1 CRISPR/Cas9: A Genome Editing Tool -- 3.2 Mechanism of CRISPR/Cas9 Genome Editing -- 3.3 CRISPR/Cas9-Mediated Nonalcoholic Fatty Liver Disease (NAFLD) Models -- 3.3.1 Transmembrane 6 Superfamily 2 (TM6SF2)-Targeted Fatty Liver Disease Models -- 3.3.2 PNPLA3-Targeted Models -- 3.3.3 Miscellaneous Models -- 4 ``Good Fit´´ Genome Editing Tool Selection for ALD and NAFLD Variant Replication -- 4.1 Cutting-Edge Cas9 Variants -- 4.1.1 Base Editor for Fatty Liver Disease Genome Variants -- 4.1.2 Prime Editor for ALD and NAFLD Genome Variants -- 4.2 Gene Delivery Methods for Refining Efficacy of Gene Editing Process -- 4.2.1 Nonviral Delivery Methods -- 4.2.2 Viral Delivery Methods -- 5 Discussion -- 6 Future Implications -- 7 Conclusions -- References. Genomic Editing and Diabetes. |
| Record Nr. | UNINA-9910633913003321 |
| Singapore : , : Springer, , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
MicroRNA Signaling
| MicroRNA Signaling |
| Autore | Cretoiu Dragos |
| Pubbl/distr/stampa | Frontiers Media SA, 2020 |
| Descrizione fisica | 1 electronic resource (260 p.) |
| Soggetto topico |
Science: general issues
Biology, life sciences |
| Soggetto non controllato |
microRNA
signaling disease circulating microRNA hypertrophy |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910557464903321 |
Cretoiu Dragos
|
||
| Frontiers Media SA, 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Muscle Atrophy [[electronic resource] /] / edited by Junjie Xiao
| Muscle Atrophy [[electronic resource] /] / edited by Junjie Xiao |
| Edizione | [1st ed. 2018.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2018 |
| Descrizione fisica | 1 online resource (618 pages) |
| Disciplina | 612.74 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Molecular biology
Cell biology Human physiology Molecular Medicine Cell Biology Human Physiology |
| ISBN | 981-13-1435-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | An overview of muscle atrophy -- Myofibers -- Muscle mass, quality, and composition changes during atrophy and sarcopenia -- Muscle changes during atrophy -- Skeleton muscle damage in intorauterine growth restriction -- The role of IGF-1 signaling in skeletal muscle atrophy -- mTOR signaling pathway and protein synthesis: from training to aging and muscle autophagy -- Past, present and future perspective of targeting myostatin and related signaling pathways to counteract muscle atrophy -- Hormones and muscle atrophy -- Ubiquitin-proteasome pathway and muscle atrophy -- Noncoding RNAs in muscle atrophy -- NF-kB and inflammatory cytokine signalling; role in skeletal muscle atrophy -- Redox homeostasis in age-related muscle atrophy -- Disturbed Ca2+ homeostasis in muscle wasting disorders -- Muscle atrophy in cancer -- The molecular mechanisms and prevention principles of muscle atrophy in aging -- Muscle atrophy in cardiovascular diseases -- Muscle atrophy in chronic kidney diseases -- Sarcopenia in liver disease: current evidence and issues to be resolved -- Muscle atrophy measurement as assessment method for low back pain patients -- Drugs of muscle wasting and their therapeutic targets -- Nutritional support to counteract muscle atrophy -- Nutritional considerations in preventing muscle atrophy -- Physical exercise for muscle atrophy -- To contrast and reverse skeletal muscle atrophy by Full-Body In-Bed Gym, a mandatory life-style for older olds and borderline mobility impaired persons -- Overview of FES-assisted cycling approaches and their benefits on functional rehabilitation and muscle atrophy -- The reversal of atrophy in human skeletal muscles by home-based Functional Electrical Stimulation after complete SCI lower motor neuron denervation -- Preverting muscle atrophy following strokes- a reappraisal -- Muscle atrophy: present and future. |
| Record Nr. | UNINA-9910298438803321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Non-coding RNAs in Cardiovascular Diseases [[electronic resource] /] / edited by Junjie Xiao
| Non-coding RNAs in Cardiovascular Diseases [[electronic resource] /] / edited by Junjie Xiao |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (VII, 426 p. 27 illus., 23 illus. in color.) |
| Disciplina | 612.1 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Molecular biology
Human genetics Cardiology Molecular Medicine Human Genetics Malalties cardiovasculars RNA |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-1671-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Section I Overview -- 1. An overview of non-coding RNAs and cardiovascular system -- Section II Bioinformatics and Interactions -- 2. Bioinformatics research methodology of non-coding RNAs in cardiovascular diseases -- 3. Online databases and non-coding RNAs in cardiovascular diseases -- 4. Interactions among non-coding RNAs involved in regulating of cardiovascular diseases -- 5. RNA-binding proteins (RBPs) and non-coding RNAs in cardiovascular diseases -- Section III Non-coding RNAs regulation in cardiovascular system -- 6. Involvement of epigenetic control and non-coding RNAs in cardiovascular system -- 7. Non-coding RNAs as Epigenetic Gene Regulators in Cardiovascular Diseases -- 8. Non-coding RNAs and physiological cardiac hypertrophy -- 9. Non-coding RNAs and cardiac regeneration -- 10. Role of non-coding RNA in diabetic cardiomyopathy -- 11. Comprehensive overview of non-coding RNAs in cardiac development -- Section IV Non-coding RNAs and Cardiovascular diseases -- 12. Non-coding RNAs and heart failure -- 13. Non-coding RNAs and pathological cardiac hypertrophy -- 14. Non-coding RNAs and cardiac aging -- 15. Non-coding RNAs and ischemic cardiovascular diseases -- 16. Non-coding RNAs and coronary artery disease -- 17. Non-coding RNAs and cardiac arrhythmias -- 18. Non-coding RNA and cardiac electrophysiological disorders -- 19. Non-coding RNAs and atrial fibrillation -- 20. Y RNAs: Biogenesis, Function and Implications for the Cardiovascular System -- 21. Translational potential of non-coding RNAs for cardiovascular disease -- Section V Potential biomarkers and Therapeutic implications -- 22. Circulating non-coding RNAs and Cardiovascular Diseases -- 23. Small interfering RNAs and RNA therapeutics in Cardiovascular Diseases -- Section VI Future Prospects -- 24. Prospective advances in non-coding RNAs investigation. |
| Record Nr. | UNINA-9910409698703321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Physical Exercise for Human Health [[electronic resource] /] / edited by Junjie Xiao
| Physical Exercise for Human Health [[electronic resource] /] / edited by Junjie Xiao |
| Edizione | [1st ed. 2020.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 |
| Descrizione fisica | 1 online resource (ix, 459 pages) : illustrations |
| Disciplina | 613.7 |
| Collana | Advances in Experimental Medicine and Biology |
| Soggetto topico |
Human physiology
Sports sciences Health promotion Human Physiology Sport Science Health Promotion and Disease Prevention Exercici Salut |
| Soggetto genere / forma | Llibres electrònics |
| ISBN | 981-15-1792-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Chapter 1. An overview of the beneficial effects of exercise on health and performance -- Chapter 2. Type of exercise training and training methods -- Chapter 3. Molecular mechanisms mediating adaptation to exercise -- Chapter 4. Exercise and organ crosstalk -- Chapter 5. Exercise and Hyperlipidemia -- Chapter 6. Exercise and Type 2 diabetes -- Chapter 7. Exercise and Type 1 Diabetes -- Chapter 8. Exercise and Polycystic ovarian syndrome -- Chapter 9. Exercise and insulin resistance -- Chapter 10. Exercise and Hypertension -- Chapter 11. Exercise and Coronary heart disease -- Chapter 12. Exercise and Peripheral Arteriosclerosis -- Chapter 13. Exercise and Stroke -- Chapter 14. Exercise and cardiovascular protection -- Chapter 15. Exercise and Osteoarthritis -- Chapter 16. Exercise and Chronic Pain -- Chapter 17. Exercise and muscle atrophy -- Chapter 18. Exercise and Depressive disorder -- Chapter 19. Exercise and Parkinson’s disease -- Chapter 20. Exercise and Dementia -- Chapter 21. Exercise and Schizophrenia -- Chapter 22. Exercise and Multiple Sclerosis -- Chapter 23. Exercise and anxiety -- Chapter 24. Exercise and Chronic obstructive pulmonary disease (COPD) -- Chapter 25. Exercise and Asthma -- Chapter 26. Exercise and Cystic fibrosis -- Chapter 27. Exercise regulates the immune system -- Chapter 28. Effects of Exercise on the immune function, quality of life and mental health in HIV/AIDS individuals -- Chapter 29. Effects of Exercise on Memory Interference in Neuropsychiatric Disorders -- Chapter 30. Effects of Exercise on Long-Term Potentiation in Neuropsychiatric Disorders -- Chapter 31. Prospective advances in beneficial effects of exercise on human health. |
| Record Nr. | UNINA-9910409695503321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2020 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||